Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire

Executive Summary

Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.

You may also be interested in...



Pandemic Clinical Trials Need More Top-Down Control, Gottlieb Says

Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.

Lilly’s EUA Timeline For COVID-19 Combo Antibody Depends On Safety Data, Manufacturing

Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.

Regeneron Pushes Legal, Ethical Boundaries With Offer Of COVID-19 Antibody To Biden Campaign

Company may have violated FDA’s preapproval promotion restrictions by discussing compassionate use option with Joe Biden’s team and by publicizing it on TV, highlighting the fine line between making the general public aware of expanded access and touting an investigational product as useful for a particular illness.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel